In 2016, the pace of biological insights into small-cell lung cancer (SCLC) was reflected in new treatment approaches that have suggested meaningful clinical benefit to patients. We focus on three highlights of 2016: preclinical studies defining NFIB as a putative driver of metastasis, and two clinical studies; one that assessed the efficacy of an agent targeting the Notch ligand DLL3, and the other that explored T-cell checkpoint-blockade therapies targeting PD-1 and CTLA-4.
This is a preview of subscription content, log in via an institution to check access.
References
Denny, S. K. et al. Nfib promotes metastasis through a widespread increase in chromatin accessibility. Cell 166, 328–342 (2016).
Semenova, E. A. et al. Transcription factor NFIB is a driver of small cell lung cancer progression in mice and marks metastatic disease in patients. Cell Rep. 16, 631–643 (2016).
Wu, N. et al. NFIB overexpression cooperates with Rb/p53 deletion to promote small cell lung cancer. Oncotarget http://dx.doi.org/10.18632/oncotarget.11583 (2016).
Rudin, C. M. et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, open-label, phase I study. Lancet Oncol. http://dx.doi.org/10.1016/S1470-2045(16)30565-4 (2016).
Antonia, S. J. et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 17, 883–895 (2016).
Dooley, A. L. et al. Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev. 25, 1470–1475 (2011).
George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47–53 (2015).
Saunders, L. R. et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci. Transl Med. 7, 302ra136 (2015).
Reck, M. et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2016.67.6601 (2016).
Weiskopf, K. et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J. Clin. Invest. 126, 2610–2620 (2016).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
C.M.R. has been a paid consultant regarding oncology drug development for BMS, Celgene, Chugai, Harpoon, and Novartis. J.T.P. declares no competing interests.
Rights and permissions
About this article
Cite this article
Rudin, C., Poirier, J. Shining light on novel targets and therapies. Nat Rev Clin Oncol 14, 75–76 (2017). https://doi.org/10.1038/nrclinonc.2016.203
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.203
- Springer Nature Limited
This article is cited by
-
First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
BMC Cancer (2023)
-
Significance of spread through air spaces in small cell lung cancer
Journal of Cancer Research and Clinical Oncology (2023)
-
Evaluation of circulating small extracellular vesicle-derived miRNAs as diagnostic biomarkers for differentiating between different pathological types of early lung cancer
Scientific Reports (2022)
-
Biochanin A inhibits lung adenocarcinoma progression by targeting ZEB1
Discover Oncology (2022)
-
High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy
Lung (2020)